Pfizer and BioNTech Report the CHMP’s Positive Opinion of Comirnaty JN.1 Vaccine for COVID-19
Shots:
- The CHMP has granted positive opinion to Omicron JN.1-adapted COVID-19 vaccine, Comirnaty JN.1, for subjects ≥6mos. of age, following the WHO & EMA recommendations to update vaccines for the 2024-2025 campaign targeting the SARS-CoV-2 variant JN.1
- The opinion was supported by safety & efficacy data from clinical, non-clinical & RWE studies of COVID-19 vaccines, demonstrating enhanced response against various Omicron JN.1 variants such as KP.2, KP.3 & others vs the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine
- Both companies are initiating rolling applications with the US FDA, seeking approval for their Omicron KP.2-adapted COVID-19 vaccines for individuals (≥6mos.)
Ref: Pfizer | Image: Pfizer
Related News: Pfizer Reports the P-III Trial Data of Fordadistrogene Movaparvovec for Duchenne Muscular Dystrophy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
